In response to: http://www.cyto.purdue.edu/hmarchiv/current/2446.htm You might want to consider the following combination: CD20/CD10/CD45/CD38 (if you have 4-color capabilities),for R/O CLL, as well as other malignant lymphomas. Consider: It is possible that the heretofore limited use of CD38 as described in the papers you allude to is due to the ubiquity and heterogeneity of its expression, in terms of antigen density and lineage perfidy (i.e., it binds to _everything_). 1) Use of this combination in the context of CLL would allow you to examine CD38 expression on dim CD20-cells (characteristic of CLL) as opposed to CD19, with which the differences in antigen intensity are not as striking. "Backgating" on the dim CD20 population will allow more specific analysis of the CLL subpopulation. 2) As alluded to in another response to this thread, CD38-bright expression will help in localizing plasma cells in the context of possible dyscrasias. 3) The use of CD20/CD10/CD38 is a valuable tool in cases of multiply-modal CD19-expressing populations, one of which may be hematogones, which would co-express CD10/CD38 and demonstrate disparity between the pan-B cell antigens CD20 (reduced in comparison to) /CD19. The location of these populations in CD45 versus side-scatter space will further aid in this detection. -------------------------------------------------------- Marc Langweiler Dartmouth-Hitchcock Med. Ctr. Laboratory - Flow Cytometry 603-650-7205 --------------------------------------------------------
This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:01:38 EST